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This paper relates the practice of open innovation in small R&D active chemical
companies to firm performance in terms of employment and financial position.
This relationship is examined during a period of economic downturn and applied
to the Belgian situation. The Belgian case is interesting since it is characterised by
a high economic importance of the chemical industry and a strongly developed
national (eco-) innovation system in the sector.According to their different evolution
over the last decade, a distinction is made between basic chemicals and
pharmaceuticals. In termsof open innovation strategy,adistinction ismadebetween
companies innovating completely internally (closed innovators), firms engaged in
R&D outsourcing, firms engaged in research cooperation, and firms integrating
outsourcing and cooperation in their knowledge sourcing strategy.After controlling
for abroad rangeofR&Dcharacteristics,we found that firmsengaged inoutsourcing
or having an integrated open innovation approach performed better in terms of
the evolutionof employmentduring theperiod 2005-2010.Also, theanalysis revealed
firms having a formal R&Dmanager and a long-term research vision more often
combineaverage to strongemploymentgrowthwithaprosperous financial position.
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Open innovation and firm performance in
small-sized R&D active companies in the
chemical industry: the case of Belgium
to external knowledge and brings it into relation
with firm performance. The focus is on small-
sized firms in the chemical industry with Belgium
as test case. The chemical industry in Belgium
and Europe is characterized by declining market
shares in the worldwide production and an
increased importance of pharmaceutical
business compared to basic chemicals.
Narula (2004) highlights a duality small firms
are faced with when deciding to engage in
external knowledge exchange in their innovation
strategy. On the one hand, there is a challenge
of lack of internal critical mass to deal with
increasing budget requirements, complexity and
risk. On the other hand, the engagement in
external knowledge interactionmight turn these
firms into a vulnerable position in terms of
knowledge leakage. This fits into the quest for
equilibrium between research cooperation, R&D
Introduction
Innovation becomes increasingly complex
and budgets and risks related to innovation force
companies to carefully consider the use of
external knowledge as a complement to in-
house innovative activities. This challenges
innovation management (Chesbrough, 2006)
since innovation becomes increasingly
‘distributed’ over various partners (von Hippel,
1988; Coombs et al., 2003) and ‘open’ in a way
that firms adapt their business model in favour
of both outside-in and inside-out exchange of
specialized knowledge (Chesbrough, 2003).
This paper addresses research cooperation
and outsourcing of R&D in the chemical industry.
More particularly it classifies the innovation
strategy according to the degree of openness
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motives to engage in research cooperation
mainly are threefold. Primarily, research
collaboration enables the exploitation of
economies of scale and scope in R&D, hereby
reducing innovation costs and allowing to share
risks (Röller et al. 1997). However, Cassiman et
al. (2002) emphasize that in order to successfully
co-operate, a sufficient degree of benefits of the
properly or jointly generated knowledge (issue
of knowledge appropriability and protection) is
required to reduce free-rider possibilities by
outsiders (see also Kesteloot and Veugelers, 1995
and Martin, 2002). Second, research cooperation
is expected to improve the learning efficiency
in absorbing external knowledge which fosters
knowledge spillovers and the impact on
innovative performance of incoming spillovers
(Arrow, 1962; Romer, 1990). Finally, according to
Hagedoorn (1993), research cooperation may
facilitate access to knowledge which does not
spill over and cannot easily be contracted
through market transactions, i.e. intangible or
tacit knowledge and know-how (see also
Katsoulakos and Ulph, 1998).
R&D outsourcing refers to a broad range of
activities involving procurement of routine
services, technology acquisition, commissioned
or joint research (Odagiri, 2003). During the past
decades an upsurge in outsourcing R&D has
taken place (Jones, 2000; Narula, 2004; Lai et
al., 2009;Huang et al., 2009) and it is increasingly
viewed as part of strategic decision making
(Chesbrough et al., 2006 ; Howells et al., 2008).
R&D outsourcing aims at capitalizing on external
knowledge - that is internally not available or
that can’t be produced internally in a cost-
effective way (Mol, 2005) - which can be licensed
or bought (Gassmann, 2006). An important
distinction in R&D outsourcing activities relates
to core and non-core R&D activities. Non-core
activities (mainly codified and relatively simple
– Kogut and Zander, 1992) offer the opportunity
to direct managerial attention and resource
allocation to those tasks firms do best (Narula,
2001). Outsourcing core activities facilitates
access to new knowledge and new technology
complementary to internal capabilities. Similar
to cooperation, following Teece (1986) and
Chesbrough et al. (2006), outsourcing core
activities occurs only in case sufficient
appropriation of outsourced R&D is guaranteed.
In this respect, outsourcing process-oriented
tasks can help the firm in attaining more
innovative R&D for any given level of investment
(Friedman, 2010).
outsourcing and internal R&D.
The central research question addressed is
whether differences in the engagement in
external knowledge interactions influence the
firm’s performance. The analysis is based on a
representative sample of small firms in the
chemical industry in Belgium. The period under
consideration covers the years 2005-2010. The
companies’ research profile at the beginning of
this period is brought into relation with firm
performance during this period. Firm
performance is accounted for by means of the
evolution in terms of overall firm employment
and in terms of the financial position at the end
of the period. The specificities of small firms in
the chemical industry in Belgium as well as the
setting of a financial and economic crisis are
accounted for.
The paper is organized as follows. Section 2
provides an overview of the actual insights and
understandings related to the place of research
cooperation and R&D outsourcing in the firm’s
innovation strategy and the particularities of
small firms in the chemical industry in Belgium.
Section 3 presents the database. The empirical
analysis on the relation between innovation
behaviour and firm performance forms the
subject of Section 4. Reflections on implications
for R&D management in small firms in the
chemical sector conclude the work (section 5).
2 Open innovation in small firms in the
chemical industry
2.1 Research collaboration and R&D outsourcing
The literature on ‘distributed’ (von Hippel,
1988) and ‘open’ innovation (Chesbrough, 2003;
Chesbrough et al. 2006; Hunter and Stephens,
2010) emphasizes research cooperation and R&D
outsourcing as important forms of external
knowledge to complement the internal research
base. Howells et al. (2003) relate this to a
mounting competitive pressure for developing
new products and processes combined with
growing complexity and increased knowledge
intensity (for a more recent overview see Huang
and Rice, 2009).
Cohen and Levinthal (1990) define research
cooperation as formal and informal ways of
collaboration in which knowledge is generated
that contributes to the internal knowledge base
or in which the exchange of internally developed
knowledge takes place (see also Veugelers and
Cassiman, 1999; Coombs et al., 2003). The firm’s
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cooperation involve certain risks in terms of
losing leadership in scientific innovation and
diminishing firm abilities to influence the
direction of the innovation the R&D will aim at
(Friedman, 2010). Another hampering factor for
completely relying on internal innovation in
small firms relates to restricted possibilities to
recruit specialized workers (Rothwell and
Dodgson, 1991). This drives small sized firms to
rely on networks to identify and to make
advantage of missing innovation resources
(Vossen, 1998). 
Gassmann et al. (2010) highlight a trend
toward more R&D outsourcing and research
cooperation which is reflected in an increased
labour division in innovation. Simultaneously,
a shift is witnessed from cost reduction to
enhancement of value creation by means of
inter-organisational relationships (Enkel, 2010).
Small firms are challenged to cope with the
induced trend of professionalising the internal
processes to manage open innovation more
effectively and efficiently in combination with
limited internal resources. Narula (2004) refers
to a threshold level of internal capacity to absorb
the externally acquired information, involving
both the availability of R&D experts and (in
particular with regard to tacit knowledge
developed and exchanged in research
cooperation) managerial resources.
2.3 Small firms in the chemical industry in
Belgium
During the period under study, the years 2005
till 2010, the world manufacture of ‘chemicals
and chemical products (including
pharmaceuticals)’ is characterized by an on
average moderate but unequal growth rate
across the globe. In this period, the world’s up-
and-coming economies (more specifically Asia-
Pacific) have been gradually overtaking the US
and EU and hence have been impacting heavily
on the increased average world production (Cefic,
2011a; Datamonitor, 2011a).
The spill-over effects of the global economic
downturn of 2008-2009 have had a strong
impact on the overall chemical market. Data
about the European chemical industry’s activity
through 2009 indicate that some companies
were experiencing a large pressure on their profit
margins, which was particularly due to the lack
in both customer demand and consumer
spending (Cefic, 2011a). Except for Asia-Pacific,
all regions had a negative growth rate in 2008
An important element in firm decision to
engage in cooperation or R&D outsourcing is
the distribution of (research and innovation)
competences at firm level between research
cooperation, R&D outsourcing, and in-house
R&D. This involves balancing the use of external
knowledge relations to explore new research
areas with relatively less capital and lower risk
involvement in case of failure with the risks of
knowledge leakage and a deterioration of
technological competitiveness. To minimize the
latter risks, successful cooperation and
outsourcing can be supposed conditional upon
a sufficient internal R&D absorptive capacity
(Cohen and Levinthal, 1990).
2.2 Small firms
In contrast with the ample attention paid to
the study of open innovation in large
(multinational) enterprises, relatively little is
known about its implementation in small firms
(Gassmann et al., 2010). Moreover, the benefits
of open innovation in small firms are not
straightforward. On the one hand, small sized
firms present a higher R&D productivity because
of their flexibility to exploit more efficiently
knowledge generated outside the firm (see e.g.
Audretsch and Vivarelli, 1996; Laursen and Salter,
2004). On the other hand, the absolute size
limitations which may be enhanced by
tendencies towards cross-border competition
and multiple technological competences may
be an important hampering factor for engaging
in external knowledge interactions (Narula,
2004). 
van de Vrande et al. (2009), using a sample
of Dutch SMEs, put forward evidence that open
innovation practices - among which external
networking and R&D outsourcing - gained
importance during the period 1999-2005.
However, the implementation of open innovation
practices is not without consequences.
Compared to large firms, small firms are faced
with balancing more limited resources to a wide
range of aspects of the value chain in order to
effectively market externally sourced and
internally developed knowledge. Moreover,
Narula (2004) clarifies that the potential loss
of technological assets as a major issue
particularly applies to research cooperation. This
can be related to the necessity to guarantee and
maintain outstanding internal competences in
only a few or even a single technological area.
Hence, R&D outsourcing and research
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terms of value both in 2005 and 2010, followed
by the pharmaceuticals subsector that had
gained largely in importance in this five year
period. This trend had been going on for some
time (Essencia, 2008, Datamonitor 2005 and
2011b). The Belgian chemical industry has one
of the highest degrees of specialization in the
world and is one of the most integrated chemical
clusters (FPS Economy, 2012). Belgium only
represents about 2.7% of the European GDP and
2.1% of the total EU-27 population. However, the
total Belgian chemical industry (including
pharmaceuticals) covered in 2008 about 6% of
the total EU-27 turnover, 6% of total investments,
and 14% of the EU-27 total extra-European
exports of chemical products (Essenscia, 2008).
The comparatively very high level of Belgian
chemical exports can be explained by the fact
that many multinational firms use Belgium as
an international transit centre, which implies
that import-export trade in chemical products
(especially pharmaceuticals) far outweighs the
value of the domestic market (Ecorys, 2009).
Furthermore, in 2009, Belgium was the number
one country in the world producing chemical
products (including pharmaceuticals) on a per
capita basis and 11 of the world’s top 15 chemical
companies had invested in Belgium by
establishing production sites (Essenscia, 2011a).
In 2010, the Belgian chemical industry (largely
taken) accounted for a quarter of all the Belgian
industrial activity, and employment in the sector
remained stable in the past twenty years. The
number of jobs in Belgian chemicals fell in 2009
- a year with difficult economic conditions - with
3.6% , to some 91,500 direct jobs. However, these
job losses were lower than for the general
manufacturing industry (-5.2%) (Essenscia,
2011b).
Based on national account data for Belgium
(Belfirst – accessed August 2012) small firms (i.e.
firms with less than 50 employees) accounted
for 70% of all firms in the industry in 2005.
During the period 2005-2010 their share
remained relatively stable (1% increase). In terms
of employment, by the year 2010, the firms
categorised as small firms in 2005 increased
their employment with 15% compared to an
overall decrease with 3% in the sector over this
period. In terms of number of firms, the weight
of basic chemicals compared to pharmaceuticals
is about five to one. Small firms in basic
chemicals account for 72% of the number of
firms and during the period 2005-2010 their
employment increased with 10% compared to
and 2009 in their production figures for the
chemical industry as a whole (Cefic, 2011a). This
negative trend, however, was not equal for all
subsectors. In Europe, the economic crisis mainly
affected the production of the subsectors
inorganic base chemicals, petrochemicals and
polymers, because these  segments are much
more dependent on business cycles than other
chemical subsectors. In this respect, and in 2010,
these subsectors experienced a stronger recovery
than consumer and specialty chemicals (Cefic,
2011a). As in most other industrial sectors, the
economic crisis caused many chemical
companies as well as governmental institutions
to diminish their activity and reconsider their
R&D-projects related to the chemical industry.
However, this approach always carries the risk
of introducing too many short-term cost-
containment measures that importantly
compromise the stability and predictability
necessary for the chemical industry (and
especially pharmaceuticals industry) to work
efficiently (Efpia, 2010).
According to size classes, the European
chemical industry consists of one fourth of small
sized firms (i.e. 10 to 50 employees). Together
with micro-sized firms (less than 10 employees)
these firms accounted for over eighty
(respectively seventy) percent of all companies
in basic chemicals (respectively
pharmaceuticals), which means the total
European chemical industry is characterized as
an industry with many SMEs (Ecorys, 2009; Cefic,
2010). As SMEs typically lack the resources to
conduct all steps in the ‘production’ of a good,
from basic research through to marketing and
distribution, they often specialize in innovation
relating to a well-defined and narrow field. This
also applies to the pharmaceuticals sector, where
SMEs tend to focus on specific formulations of
pharmaceutical products and often out-license
or sell their innovations to larger companies
that have the required resources, necessary for
clinical trials and marketing (European
Commission, 2009).
Belgium, one of the smallest European
countries, is one of the largest world producers
of chemicals and has been a home base for the
chemical industry thanks to major innovations
in the 19th and 20th century (Essenscia, 2011a).
As a result, a diverse portfolio of chemistry-based
industrial activities (including pharmaceutical
activities) has developed in Belgium over the
past two centuries (Essenscia, 2008). The basic
chemicals segment was the largest segment in
that is of crucial importance for the development
of research and innovation (Cooke, 1992 and
2005) and for the enhancement of open
innovation. As for knowledge sourcing and
interaction, this ‘regional dimension’ is
particularly important for the many SMEs within
the chemical and pharmaceuticals industry
because joint collaboration through all kinds of
‘open innovation’ initiatives carry substantially
larger risks than is the case for larger companies
(Incerti, 2008). The ample collaborations and
synergies between the medical and academic
worlds and the (bio) pharmaceutical research
companies in Belgium generate a prosperous
climate for the R&D of therapeutic innovations
(Friedman, 2010), and the key contribution of
this R&D in the pharmaceuticals sector is “to
turn fundamental research into innovative
treatments that are widely available and - even
more importantly - accessible to patients” (Efpia,
2010, p. 5). Moreover, the ‘in-house’ research of
SMEs is increasingly challenged because
innovation often happens at the interface of
several disciplines, with this scientific
interdisciplinarity being extremely important
for the innovative potential and hence future
of the chemical industry (Essenscia, 2009). 
2.4 Research focus
The focus in this paper is on R&D active small
companies in the chemical industry. The central
research question is whether differences in the
engagement in external knowledge interactions
influence these firms’ performances during a
period of economic downturn. More specifically
the R&D active small companies will be divided
in closed innovators, innovators engaged in
outsourcing, innovators engaged in cooperation,
and integrated innovators (i.e. companies
engaged both in R&D outsourcing and research
cooperation).
Two aspects of economic performance will
be taken into account. The main focus will be
on the evolution of firm employment during the
period under consideration. However, it is clear
that the crisis also brought financial constraints,
and this especially for risky and long-term
oriented R&D activities in SMEs.
In Europe, most companies - large and small
- reported large drops in demand since
November 2008. However, most companies also
had business areas that were less affected by
this decrease in demand (European Parliament,
2009). The literature provides somewhat
a sector reduction with 8%. Small firms in
pharmaceuticals account for about three fifth
of the enterprises and their employment
increased with close to 60% compared to a
sector average of 15%. As for the companies in
the pharmaceuticals sector, Belgium had in 2010
more than 200 biotech and pharmaceutical
firms, ranging from big pharmaceutical
corporations to a large network of SMEs that
specialize in all areas of biopharmaceutical
fundamental and clinical research and
manufacturing (FPS Economy, 2012). Because of
these companies, Belgium was ranked in 2010
in the top 10 of most innovative
(bio)pharmaceutical valleys in the world.
Six main reasons can be identified for
Belgium being an attractive place for the
chemical industry (Abrahamsen, 2011, Essenscia,
2011a and 2011b and FPS Economy, 2012): Belgium
constitutes a unique logistical platform in the
heart of Europe; it has a highly skilled labour
force with world-class technical expertise for
product and process technology and operational
excellence; it provides attractive - including R&D
- tax incentives for foreign investors; it developed
a unique network to implement REACH
(Registration, Evaluation and Authorisation of
Chemicals) & CLP (Classification, Labelling and
Packaging of substances and mixtures) which
are both aimed at providing exchange of
experience, knowledge and information between
the chemical industry, the industry regulators
and the service providers and at coordinating
communication throughout the supply chain;
it hosts and funds some of the major global and
European research centres and a number of
competence centres relating to the different
segments of the chemical industry and there is
a strong collaboration between the Belgian
chemical industry and Belgian - and other
countries’ - universities and top scientists, and
there are many academic spin-off companies;
and finally, the relatively high R&D investments
in the Belgian chemical industry prepare the
Belgian chemical industry for top-end innovation
and are directed towards sustainable innovation,
which in turn makes it possible for the many
SMEs in the Belgian chemical industry to grow
and innovate thanks to collaborating with other
firms, research institutions and universities. The
latter reasons refer to the strong regional
innovation (eco)system - and more specifically
the interactions with private and public research
organizations - available in the Belgian chemical
industry (see also Teirlinck and Spithoven, 2008)
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opposite and conflicting views with regard to
the economic performance of small firms in
times of crisis, and some researchers argue that
small enterprises are more affected by the crisis
than large firms. Generally speaking, because
larger companies often have more potential for
diversification, the economic crisis-related
decrease in demand may not hit them as hard
as is the case for highly specialized companies
serving volatile markets. Moreover, while many
large companies were finding it difficult and
expensive to obtain major credit lines, SMEs
were having even greater difficulties in obtaining
guarantees and credit letters for imports and
exports. As a result of the above, the credit
ratings for a number of chemical companies
have been downgraded, which has in turn
prompted the banks to re-evaluate the entire
industry (KPMG International, 2010).
However, according to others, and contrary
to the general view above, in the chemical
industry, the SMEs were less affected by the
crisis than large chemical firms. In the chemical
industry - and mainly this industry not including
pharmaceuticals - the majority of the SMEs was
not focused on a specific downstream industry
at the beginning of the economic crisis and some
SMEs were operating in niche markets, less
affected by the crisis, which made them more
‘robust’ to overcome adversities in times of crisis.
Moreover, to get over the crisis, the small
chemical SMEs took fewer risks and they even
used the recent boom to improve their capital
base. On average, the chemical SMEs were also
better equipped to deal with the consequences
of the crisis than larger companies, because they
were less active in the production of basic
chemicals, the production segment that was
affected the most by the crisis. The larger
chemical companies were more strongly affected
by the crisis, as due to past acquisitions, buyouts
and stock buybacks, the chemical sector was
more leveraged than before and therefore badly
positioned to deal with these adversities,
resulting in bankruptcy for some, while others
were forced to sell their assets to pay their debts.
In other words, it seems that SMEs in the
chemical industry were better prepared for the
adverse economic environment resulting from
the crisis than some of their larger counterparts
(European Parliament, 2009). These findings
were confirmed in section 2.3.
3 Survey
The starting point for the empirical analysis
is firm-level data on R&D in small enterprises
in the chemical industry in Belgium in the year
2005. Following the EU definition (as from
January 2005), a small firm is defined as a firm
having less than 50 employees; an annual
turnover or balance sheet not exceeding 10
million euro; and being autonomous in the sense
that it is completely independent or has one or
more minority partnerships (each less than 25%)
with other enterprises. For the latter it should
be noted that a company may still be ranked as
autonomous in case the 25% threshold is reached
or exceeded by public or institutional investors. 
The empirical section in this paper puts into
relation the openness of these companies for
research cooperation and R&D outsourcing on
the one hand and firm performance on the other
hand. Data regarding research behaviour is
provided by the bi-annual OECD business R&D
survey for Belgium. This internationally
standardized postal survey collects data
regarding R&D (employment, cooperation,
outsourcing …) and does so in a way to cover the
population of permanent R&D active firms. Firms
are classified into the chemical industry if (the
bulk of) their R&D is performed in this business.
The presented analysis is based on the R&D
survey organized in the year 2006 and offering
results for the period 2004-2005. The starting
point is all permanent R&D active small firms
in the chemical industry in Belgium in the year
2005. This information will help to create a
profile of ‘openness’ to external knowledge for
each company. The information is linked with
information regarding firm performance from
the annual account database (based on Belfirst)
for the period 2005-2010. The aim is to identify
differences in performance according to
differences in research profile. In terms of
performance, both the evolution in employment
and the firm’s financial situation will be
accounted for.
The starting point of the analysis is the
official population of small firms engaged on a
(quasi-) permanent basis in R&D activities mainly
related to the chemical industry in Belgium in
the year 2005. Based on the official OECD bi-
annual business R&D survey for Belgium a
population can be derived consisting of 100
enterprises. For each of these enterprises the
R&D budget and personnel is known or can be
accurately estimated based on previous and
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more recent information (for more details see:
Commission Coopération Fédérale, 2001). These
companies’ performance is investigated during
the period 2005-2010. In order to give an accurate
picture, firms that were part of a merger or
acquisition during this period are excluded (6
companies are involved). Eight companies (or
one out of twelve) went bankrupt. Apparently,
small firms in the basic chemicals sector have
been severely hit by the economic crisis since
all of these bankruptcies took place in the period
July 2009-December 2010. This is in line with
the earlier observation that since November
2008 the economic situation for ‘manufacture
of chemicals and chemical products (including
pharmaceuticals)’ has deteriorated dramatically
for Europe as a whole as well as in the European
countries separately. Since we have full
information for these companies for the period
2005-2010 they remain in the analysis. This leads
to a target population of 94 R&D active small
firms in the chemical industry.
The focus of this work is on the link between
the firm’s openness to external knowledge
interactions and economic performance.
Information regarding these items is available
for 67 companies. With respect to the 94 firms
in the target population this is a 70% response
rate. A comparison of the R&D personnel, R&D
expenditures, overall employment and financial
position (current ratio), and firm age revealed
no significant differences between the cases
included in the analysis and those excluded.
Therefore, we can assume there is no response
bias. We differentiate basic chemicals (41
companies) from pharmaceuticals (26
companies) because of their particularities both
in terms of activities and evolution (see section
2.3).
Compared to the population of small
companies in the chemical industry in Belgium
in 2005 which consisted of 287 companies, the
100 R&D active enterprises represented 40.5%
of the 6730 employees. During the years 2005-
2007 the total labour force of SMEs in the sector
increased with over 5%, stagnated in 2008 and
reached in 2010 a level almost 7% lower than in
2005. The share in employment of the R&D
active small firms rose in that period to 44.5%.
It is explained by a longer growth period (+12%
in the period 2005-2008) and a decrease
afterwards to arrive at a level slightly (-1%) below
the employment level in the year 2005 (based
on national account data).
4 Empirics
4.1 Profile of small R&D active companies in
the chemical industry
Figure 1 categorizes the companies according
to four degrees of openness for external
knowledge. A classification is made according
to companies that perform research in
collaboration with third parties, companies that
outsource part of their R&D activities, companies
that combine research collaboration and R&D
outsourcing (referred to in this paper as
companies with an integrated networking
strategy), and closed innovators (neither
engaging in research cooperation nor R&D
outsourcing). Research cooperation involves both
formal and informal knowledge development
and knowledge exchange in research
cooperation. R&D outsourcing relates to the
outsourcing of parts of the R&D process since
only companies are considered having an
internal R&D base (i.e. having at least a certain
level of absorptive capacity - Cohen and Levinthal
(1989)). 
For the chemical industry in its totality, close
to two-fifth of the firms has an integrated
innovation strategy. Over one fourth has a closed
innovation strategy. However, differences can
be noted between basic chemicals (only one in
three companies has an integrated strategy)
and pharmaceuticals (half of the companies has
an integrated strategy). Differences in the share
of firms with a closed strategy are more modest.
With regard to overall firm characteristics the
box plots on the right hand side of Figure 1
present the median (middle observation) and
interquartile (50% of middle values) for firm
age, average employment and the share of R&D
employment in the overall firm employment.
Differences in firm profile in terms of age and
average firm employment in relation with degree
of openness are modest. In terms of
employment, the median both in basic chemicals
and in pharmaceuticals and for each of the four
different degrees of openness is around 20
employees. In terms of age, a notable difference
is that SMEs in pharmaceuticals that cooperate
tend to be relatively younger firms whereas
cooperation in basic chemicals rather takes place
in longer established small firms. The R&D
intensity (share of R&D personnel in overall firm
employment) is higher in pharmaceuticals and
in firms engaged both in R&D outsourcing and
research cooperation (integrated strategy). Also,
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R&D outsourcing in the basic chemical industry
tends to be related to small firms with a lower
R&D intensity. The findings with regard to R&D
intensity could point to outsourcing of more
routine tasks and are a first indication for the
necessity of absorptive capacity to valorise
external knowledge, or can also refer to complex
or more advanced research activities which
necessitate input from outside the company.
4.2 Company performance
In the literature review, the evolution of firm
employment and the firm’s financial position
have been identified as important factors of
firm survival. Figure 2 associates the different
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Figure 1  Degree of openness of R&D activities in small firms in the chemical industry, 2005
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forces in the year 2005 experienced an average
employment growth during the period 2005-
2010. Firms with a more open innovation strategy
tend to be characterized by a more extreme
growth performance. This both in a negative
(weak growth) and a positive (strong growth)
sense. As such, firms that relied on a closed
strategy were more stable in terms of
employment during the period 2005-2010. In
terms of financial position, firms with an
integrated innovation strategy mainly are
situated in the comfort zone (propensity of 2:1).
Firms engaged in outsourcing or cooperation
solely as well as closed firms have a more or less
equal propensity to be in the danger zone
compared to the comfort zone.
The right hand part of Figure 2 reveals
companies in the pharmaceutical industry being
more successful both in terms of employment
and in terms of financial situation. This is in line
with the general economic tendencies for these
industries as presented in section 2.3. Companies
with a closed R&D strategy perform relatively
better in terms of the evolution of employment
in the basic chemicals whereas outsourcing
activities seem to be positively related both to
performance and to a financial buffer in the
pharmaceutical industry (as presented in Table
1). With regard to the financial buffer it should
be seen whether R&D outsourcing helps to
create an additional buffer due to cost-effective
reasons or whether a financial buffer creates
room for outsourcing. Despite the relatively low
number of observations in each cell these results
indicate that a strong engagement in external
knowledge relations is not a guarantee for
economic success at firm level and confirm
Narula’s (2004) findings with regard to
protection of internal knowledge and preference
for outsourcing activities rather than
cooperation.
4.3 Broader set of R&D determinants for
company performance 
A main objective of this paper is to relate
company performance to the degree of openness
of the innovation strategy. A good company
performance is related to a combination of a
comfortable financial position and an average
to strong growth in terms of evolution in
employment. For the total of the chemical
industry the upper left drawing in Figure 3
indicates the relation between different aspects
of the company’s (research) profile with
forms of openness in innovation strategy in the
year 2005 with firm performance in the period
2005-2010. The lagged values for research
compared to firm performance indicators
account for the fact that good firm performance
could lead to a particular behaviour in the
innovation strategy with regard to the use of
external knowledge relations. 
Firm employment is measured as the
evolution of the overall firm employment
between the year 2005 and 2010. The firm’s
financial situation is approximated by the
current ratio (total current assets/total current
liabilities) which is one of the best known
measures of financial strength. The main
question this ratio addresses is whether or not
a firm has sufficient current assets to meet the
payment schedule of its current debts with a
margin of safety for possible losses in current
assets, such as inventory shrinkage or collectable
accounts. A generally acceptable current ratio
amounts to 2 to 1. The optimum level can be
sector depending but the minimum acceptable
current ratio is obviously 1:1. In order to avoid
strong fluctuations due to exceptional situations,
the current ratio is calculated as the average
ratio for the years 2009 and 2010. This ratio is
of particular interest during a period of economic
and financial downturn. Other financial
indicators in terms of profitability and market
share have been taken into consideration.
However, based on the national account data
for Belgium these indicators are lacking for close
to half of the firms, and the indicators turned
out to largely fluctuate from one year to another.
This can be related to the fact that (unless some
exceptions) small firms in Belgium have limited
reporting duty in terms of annual accounts and
balance sheet.
Figure 2 visualizes the evolution of the firms’
performances. In terms of employment, a
distinction is made between weak performance
(negative growth – including the eight
companies that went bankrupt), average growth
(increase of employment between 0 and 33%),
and strong growth (increase with over one third
in the period 2005-2010). For the financial
position, the companies are divided in a group
of companies situated in a comfort zone (current
ratio of two and more) and those below this
threshold.
An important difference exists between
companies with a closed and those with a more
open innovation strategy. The majority of firms
that were relying solely on the internal R&D
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differences in openness in the innovation
strategy. Account is taken of firm age, formal
management (relates to the presence of an R&D
manager), absorptive capacity (share in overall
employment and the absolute number of R&D
employment), and long-term orientation (share
of research - versus development - in the R&D
expenditures). 
Firms with an integrated R&D strategy score
high on all factors, except company age (these
firms are on average younger companies). Also
closed innovators on average are younger than
firms engaged in cooperation or - in particular
- outsourcing. Companies engaged in
cooperation turn out to be more long term
oriented. However, this picture is somewhat
different for companies in basic chemicals
compared to pharmaceuticals. First, important
differences can be noticed in terms of
cooperation. Companies in the basic chemicals
engaged in cooperation are relatively more
engaged in formal R&D management, are older
and perform better compared to pharmaceutical
companies engaged in cooperation. Also closed
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Figure 2 Degree of openness of R&D activities and firm performance 
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innovators in basic chemicals perform better
and are more long term oriented in their R&D.
By consequence, in the pharmaceutical industry
cooperating firms are relatively younger, have
less absorptive capacity and perform relatively
worse. Also, firms in the pharmaceutical industry
that are engaged in outsourcing rely relatively
less on formal R&D management and firms with
an integrated strategy perform relatively better.
As could be seen from Table 1 the latter mainly
is related to a good position in employment
growth. On the right hand side of Figure 3, a
probit regression analysis presents in a more
analytical way the relationship between these
variables and the firm’s performance. As
explained before, a good company performance
(binary variable: yes-no) is related to a
combination of a comfortable financial position
and an average to strong growth in terms of
employment. The probit analysis is
complemented with a regression analysis
explaining the evolution of firm employment
over the period 2005-2010.
The probit analysis reveals openness of the
innovation strategy to exert no significant
influence on firm performance (combined
employment growth and financial position).
Turning to the R&D related variable, the presence
of formal R&D management and longer term
oriented research positively influence the firm’s
performance. By contrast, company age and
especially the share of experts in the internal
R&D personnel negatively influence firm
performance. The latter is surprising but could
be linked to the economic and financial crisis.
The overall measurement of absorptive capacity
(a combined measurement of critical mass of
R&D employment and the intensity of R&D
employment in overall firm employment) has
no significant influence on firm performance.
Of course, this should be seen in light of the fact
that only (quasi-) permanent R&D active
companies are part of the target population.
A refinement of the results in the regression
analysis explaining employment growth
provides a different picture. The analysis reveals
both R&D outsourcing and an integrated
innovation strategy at the beginning of the
period to positively influence the evolution of
overall firm employment during the period 2005-
2010. R&D outsourcing positively affects firm
employment. These findings are in line with
earlier findings by Teirlinck et al. (2010)
concluding that R&D outsourcing does not
negatively influence internal R&D employment.
Also a longer term oriented research focus
positively influences overall firm employment.
By contrast the share of highly qualified experts
in total R&D employment negatively influences
employment evolution. This could be related to
missing opportunities to valorise research
findings within the company or to highly
specialized or niche market activities in small
firms heavily relying on this type of employee
profile for R&D. Further qualitative research in
this field is advisable. Finally, a similar regression
model to explain the financial position of the
company did reveal no significant influences of
the variables under consideration. This does not
necessarily mean that the influence is absent
since the measurement of a good financial
position remains a difficult endeavour. Both a
below average and above average current ratio
may point to a weakness. The former since there
clearly is a lack of short term financial means.
The latter could point to management
incapability to make appropriate use of financial
slack (Cyert and March, 1963). 
5 Reflections on implications for R&D
management in small firms in the
chemical industry 
This paper examined the relation between
the use of external knowledge interactions and
performance in small firms in the chemical
industry. In a sector increasingly characterised
by internationalisation of knowledge and
research, small firms are disadvantaged due to
their absolute size limitations which may be
enhanced by tendencies towards multiple
technological competences and cross-border
competition (Narula, 2004). Moreover, high risk
and uncertainty involved in research is hard to
bear on the shoulders of small firms. Therefore,
adapting an open innovation model with
engagement in research cooperation and R&D
outsourcing may - partly - compensate limited
internal resources.
In an empirical analysis of a representative
sample of R&D active small firms in the chemical
industry in Belgium, the relationship between
the extent of engagement in open innovation
practices and firm performance has been
examined.
The Belgian chemical sector is characterised
by a strong economic importance, a high export
orientation and the presence of a broad range
of big multinational companies and research
centres and a well developed (eco) innovation
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system. Like most of the other developed
economies the sector is confronted with
increasing international competition and
decreasing market shares in the world
production. The period under consideration
covers the years 2005-2010, a period initially
characterized by economic prosperity turning
into a financial and economic crisis since the
year 2008. The openness of research activities
in the year 2005 is brought into relation with
the firm’s economic performance in terms of
employment growth as well as its financial
position.
Differentiating according to the degree of
open innovation, one fourth of the firms follows
a closed R&D approach, compared to two-fifth
combining both outsourcing and collaboration
in research. About one sixth of the firms engages
in outsourcing solely and almost one fourth
does so in research cooperation. Firms active in
basic chemicals tend to be less (one third)
engaged in a combined cooperation-outsourcing
approach compared to firms in the
pharmaceutical industry (one out of two firms).
In line with the dominant tendency in Europe
of a more positive evolution of pharmaceuticals
compared to basic chemicals in the period 2005-
2010, firms active in basic chemicals turned out
to perform weaker in terms of employment
growth and more often face a danger zone in
terms of ability to pay short term debts. In terms
of openness of the innovation strategy, closed
firms tend to perform at a more constant and
average growth rate whereas firms more open
for external knowledge interactions tend to
perform further away from the average (very
well or rather badly).
Taking into account a broad range of
additional factors, openness of the innovation
process is found to exert a positive influence on
the evolution of firm employment; however only
in case R&D outsourcing is involved. Firms solely
engaged in research cooperation do not
outperform firms following a closed R&D
strategy. In terms of a combined successful
employment evolution and a healthy financial
position, no significant influence is noted by
the degree of openness of the firm’s R&D
strategy. Elements that do matter are the
presence of formal R&D management and a
long-term vision in research activities. Also,
compared to more established firms, younger
firms face more difficulties to perform well
during a period of economic downturn. Taking
the empirical findings presented in this paper
into account, the answer to the central research
question is not straightforward: the engagement
of SMEs in open innovation practices in the
chemical industry is not a priori a reason for
later successful performance. It seems that
companies that formally manage, have a long
term orientation in R&D, and that outsource
(non-core) R&D activities outperformed their
counterparts not having these characteristics.
These results should be seen in light of the
particularities of the Belgian context and a
period of economic downturn.
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